Literature DB >> 10910802

Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study.

C DeBattista1, J A Posener, B M Kalehzan, A F Schatzberg.   

Abstract

OBJECTIVE: The primary objective of this investigation was to examine the acute antidepressant effects of intravenous hydrocortisone and ovine corticotropin releasing hormone (CRH) infusions in patients with major depression.
METHOD: Twenty-two patients who met DSM-III-R criteria for nonpsychotic major depression were randomly assigned to receive intravenously 1 mg/kg of ovine CRH, 15 mg of hydrocortisone, or saline under double-blind conditions on day 1. Standard depression rating scales were completed on day 1 before the study medications were administered and again the following day (day 2).
RESULTS: Patients treated with hydrocortisone demonstrated a significantly greater reduction in total 21-item Hamilton Depression Rating Scale scores (mean reduction=8.4 points or 37%) than patients given ovine CRH (mean=1.2 points) or placebo (mean=1.3 points).
CONCLUSIONS: Acute hydrocortisone infusion is associated with a rapid and robust reduction in depressive symptoms. The authors discuss the therapeutic implications of these findings.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910802     DOI: 10.1176/appi.ajp.157.8.1334

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  27 in total

1.  Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

2.  Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults.

Authors:  Roma A Vasa; Daniel S Pine; Carrie L Masten; Meena Vythilingam; Carlos Collin; Dennis S Charney; Alexander Neumeister; Karin Mogg; Brendan P Bradley; Maggie Bruck; Christopher S Monk
Journal:  Psychopharmacology (Berl)       Date:  2009-03-06       Impact factor: 4.530

Review 3.  The glucocorticoid receptor: pivot of depression and of antidepressant treatment?

Authors:  Christoph Anacker; Patricia A Zunszain; Livia A Carvalho; Carmine M Pariante
Journal:  Psychoneuroendocrinology       Date:  2011-04       Impact factor: 4.905

Review 4.  Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.

Authors:  Carmine M Pariante
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 5.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

6.  Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders.

Authors:  Aju Abraham; Stuart Watson; Allan H Young
Journal:  Indian J Psychiatry       Date:  2003-04       Impact factor: 1.759

Review 7.  A final common pathway for depression? Progress toward a general conceptual framework.

Authors:  Eric A Stone; Yan Lin; David Quartermain
Journal:  Neurosci Biobehav Rev       Date:  2007-10-10       Impact factor: 8.989

8.  Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters.

Authors:  Carmine M Pariante; Richard B Kim; Andrew Makoff; Robert W Kerwin
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

9.  Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers.

Authors:  Carmine M Pariante; Andrew S Papadopoulos; Lucia Poon; Anthony J Cleare; Stuart A Checkley; Judie English; Robert W Kerwin; Stafford Lightman
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

10.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.